Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.

ABSTRACT:

Objective

To report expanded 2-year follow-up of a previously reported randomized trial evaluating intravitreal 0.5 mg ranibizumab or 4 mg triamcinolone combined with focal/grid laser compared with focal/grid laser alone for treatment of diabetic macular edema (DME).

Design

Multicenter, randomized clinical trial.

Participants

A total of 854 study eyes of 691 participants with visual acuity of 20/32 to 20/320 (approximate Snellen equivalent) and DME involving the fovea.

Methods

Continuation of procedures previously reported for the randomized trial.

Main outcome measures

Best-corrected visual acuity and safety at the 2-year visit.

Results

At the 2-year visit, compared with the sham + prompt laser group, the mean change in the visual acuity letter s

SUBMITTER: Elman MJ 

PROVIDER: S-EPMC3096445 | biostudies-literature | 2011 Apr

REPOSITORIES: biostudies-literature